Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial
Titel:
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial
Auteur:
Lobo, Suzana Margareth Plantefève, Gaétan Nair, Girish Joaquim Cavalcante, Adilson Franzin de Moraes, Nara Nunes, Estevao Barnum, Otis Berdun Stadnik, Claudio Marcel Lima, Maria Patelli Lins, Muriel Hajjar, Ludhmila Abrahao Lipinski, Christopher Islam, Shaheen Ramos, Fabiano Simon, Tiago Martinot, Jean-Benoît Guimard, Thomas Desclaux, Arnaud Lioger, Bertrand Neuenschwander, Fernando Carvalho DeSouza Paolino, Bruno Amin, Alpesh Acosta, Samuel Amil Dilling, Daniel Forde Cartagena, Edgardo Snyder, Brian Devaud, Edouard Barreto Berselli Marinho, Ana Karolina Tanni, Suzana Milhomem Beato, Patricia Medeiros De Wit, Stephan Selvan, Vani Gray, Jeffrey Fernandez, Ricardo Pourcher, Valérie Maddox, Lee Kay, Richard Azbekyan, Anait Chabane, Mounia Tourette, Cendrine Esmeraldino, Luis Everton Dilda, Pierre J. Lafont, René Mariani, Jean Camelo, Serge Rabut, Sandrine Agus, Samuel Veillet, Stanislas Dioh, Waly van Maanen, Rob Morelot-Panzini, Capucine